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A radioiodinated vasopressin antagonist, d(CI-&[Tyr(MeP,Tyr(N%,)P]AVP has been prepared. Iodination was carried 
out at the phenyl moiety of the tyrosylamide residue at position 9, followed by HPLC purification. Non-radiolabelled 
monoiodinated antagonist was used as a reference for identification. lWd(CH,)~[Tyr(MeP,Tyr(N&P]AVP binding ap- 
peared to take place with a dissociation constant of 0.28 +0.09 nM (&+SD) to V, vasopressin receptors on rat liver 
membranes. 
Vasopressin; Vasopressin receptor; Iodinated vasopressin antagonist; (Liver, Kidney, Uterus) 
1. INTRODUCTION 
Receptors for the vasopressins, arginine (AVP) 
and lysine (LVP) vasopressin have been studied ex- 
tensively in liver, blood vessels and kidney. They 
have been well characterized using t3H]AVP 
and/or [3H]LVP (review [l]). Many studies on 
vasopressin receptors in tissues where they are less 
abundant have been hampered by the low specific 
radioactivity of tritiated vasopressins. Radio- 
iodinated vasopressin can be easily prepared but 
appears unsuitable for receptor studies because of 
a marked loss in affinity due to iodination. We and 
others [2,3] have shown that iodination of several 
vasopressin analogues, especially analogues with 
antagonistic properties affect only slightly their af- 
finity for vasopressin receptors. Based on these 
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observations we report here, for the first time, the 
synthesis and radioiodination of a wsopressin an- 
tagonist ([1-(,&mercapto-fl,,&cyclopentamethylene 
propionic acid), 2-(0-methyl)-tyrosine,9-tyrosyl- 
amide]arginine vasopressin: d(CH&[Tyr-(Me)‘, 
Tyr(NH~)~lAvp), with high affinity for vasopres- 
sin receptors and high specific radioactivity. 
2. MATERIALS AND METHODS 
2.1. Synthesis 
The protected precursor required for the synthesis of the 
AVP antagonist was &(benzylthio)~&cyclopentamethyl- 
ene propionyl-Tyr(Me)-Phe-Gln-Asn-Cys(BzI)Pro-Arg(Tos)- 
Tyr(Bzl)-NH2 (I). It was synthesized by coupling Tyr(Bzl)-NH2 
to the previously reported partially protected acyl heptapeptide 
precursor of desGly(NHs)9-d(CH&[Tyr(Me)“]AVP [4], as 
previously described for the related d(CHs)s[Tyr(Me)2,Thr4, 
Tyr(NH~)~lovT protected precursor [5]. The crude protected 
precursor I (455 mg) was purified by precipitation from dime- 
thylformamide/methanoI/ether, wt275 mg (42.3”10 yield), m.p. 
186-191°C (decomp.), [cu]D” = - 32.7” (Cl, DMF). Thin layer 
chromatography in three different systems showed that this 
material was pure: &(A) = 0.67; &(B) = 0.92; Rt(C) = 0.60 [A 
= butanol/acetic acid/water, 4: 1:5 (upper phase); B = 
butanol/acetic acid/pyridine/water, 15 : 3 : 3 : 10); C = chloro- 
form/methanol, 7: 31. An aliquot of I was reduced with Na/li- 
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quid NH3, reoxidiied with &[Fe(CN).& de-ionized, purified on 
Sephadex G-15 and lyophilized, as described for the parent Gly- 
NH2 analogue, d(CH&[Tyr(Me)*]AVP [6] to give the desired 
product d(&I&~yr(Me)Z,Tyr(NH2)9]AVP (AVP antagonist) 
as a fluffy white powder, 26.4 mg (22% yield), [aID” = 
-60.8” (Co.2 , 1 N NaOH), RdA) = 0.30; Rr(B) = 0.57; Rr(D) 
= 0.35 [D = butanol/acetic acid/water, 4: 1: 11. The structure 
of the peptide is the following: 
1 2 3 45 67 89 
CH2-CO-Tyr(Me)-Phe-Gin-Am-Cys-Pm-Arg-Tyr(NHz) 
CH2-c\HI I I 
iodination site 
2.2. Chloramine-T iodination 
AVP antagonist was iodinated on the 9-tyrosylamide by 
means of the oxidant Chloramine-T (Merck, FRG). AVP an- 
tagonist (2 nmol for “‘1-Na-iodination or 10 nmol for NaI- 
iodination, in 10~1 methanol) was incubated in 30~1 of 1 M 
KHzP04 buffer @H 7.5) with 1Org Chloramine-T and 1 mCi 
‘%Na (IMS-300, Amersham, Bucks, England) or 375 nm NaI 
(a quantity corresponding to 5 mCi lz51-Na). Buffer pH was 7.5 
to prevent oxidation of the disulphur bridge by Chloramine-T. 
After 30 s the reaction was stopped by immediate injection onto 
a Waters C,s-FBondapak reversed-phase column. HPLC was 
performed with a 35 mJn linear gradient of 40-75% 
trifluoroacetic acid (TFA) 0.067% in acetonitrile 60% (solvent 
B), in TFA 0.067k eolvent A). Flow rate was 1 ml/min. The 
‘%labelled peptide was further purified on a second Waters 
Cls-pBondapak reversed-phase column. The monoiodinated 
antagonist (I-AVP antagonist) was identified by the 
bathochrom shift of sthe UVLspectrum due to the monoiodina- 
tion (A,, = 304 nm). 
2.3. Bioassays 
Antagonistic activities were determined from bioassays on 
female Sherman rats weighing 185- 225 g as described in [S]. 
2.4. Peptides 40 50 60 
[‘H]AVP was obtained from New England Nuclear (Boston, 
MA). Specific radioactivity was 67.7-70.0 Ci/mmol. [“HI- 
[4-threonine,7-glycineloxytocin ([3H])-[Thr4,Gly7]OT) was 
prepared as described in [7]. Specific radioactivity was 
23.3 Ci/mmoJ. The labelled peptides were purified by HPLC 
and affinity-chromatography using a neurophysin-Sepharose 
column [8]. AVP was purchased from Bachem (Bubendorf, 
Switzerland). 
“10 solvent B in A 
Fig. 1. Elution profiles of an NaI- and an ‘*‘I-Na-iodination of 
the AVP antagonist. (a) NaI-iodination. Separation was 
performed with a linear 40-75% gradient of solvent B (0.067% 
TFA, in 60%‘0 acetonitrile) in solvent A (0.067% TFA). abs is 
the absorption measured at 254 nm. Peak 1 is the non- 
iodinated, peak 2 the monoiodinated, and peak 3 the 
diiodinated AVP antagonist. (b) ‘*‘I-Na-iodination. Separation 
was performed with a linear 40-75% gradient of solvent B 
(0.067% trifluoroacetic acid in 60% acetonitrile) in solvent A 
(0.067% TFA). Quantities are expressed in cpm. Peak 1 is non- 
covalently bound “‘1 and peak 2 the ‘251-AVP antagonist. (c) 
Purification of 1251-labelled AVP antagonist after a BSA 
incubation of 15 min. HPLC was performed as in lb. 
2.5. Membrane preparation 
Female Wistar rats (200 g body wt) were purchased from Iffa 
Credo (Lyon, France). Rat liver membrdnes were obtained ac- 
cording to the method described by Neville [9] up to step 11 and 
stored in liquid nitrogen until use.. Rat kidney membranes were 
prepared as described by Butlen et al. [IO]. Estrogenized rat 
uterus membranes were prepared as described by Elands et al. 
171. 
A 
-1111, 
B 2 
2.106. 
Quantities are expressed in cpm. 
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2.6. Binding assays 
Membranes (10-15 mg for liver, lo-65 mg for kidney and 
15 mg for uterus membranes) were incubated in 50 mM Tris- 
HCl (pH 7.4), 1, 5 or 10 mM MgCL (for, respectively, kidney, 
liver and uterus), 1 mg/ml BSA and varying concentrations of 
labelled and unlabelled peptides. Incubation at 30°C lasted 
30 min for the tritiated peptides and 40 mitt for the ‘251-labelled 
AVP antagonist. The final assay volumes were respectively 200 
and 80 ~1. Non-specific binding was determined in the presence 
of a 250-fold excess of I-AVP antagonist or a lOOO-fold excess 
of AVP. Bound and free radioactivity were separated by filtra- 
tion over Gelman (GA-3) filters for the tritiated peptides and 
over Whatman GF/C filters, presoaked in 10 mg/ml BSA (for 
at least 2 h) for the radioiodinated peptides, as described [I 11. 
Binding constants for the non-labelled AVP antagonist and the 
I-AVP antagonist were determined in competition experiments 
in the presence of 0.4-1.7 nM [‘HIAVP for liver membranes, 
1.0 nM [‘H]AVP for kidney medulla membranes and 
1.9-3.1 nM [“HI-[Thr4Gly7]OT for uterus membranes. Results 
of dose-dependent binding and competition experiments were 
analyzed using a non-linear weighted regression analysis carried 
out with ligand [12]. Kd values are expressed in nM f SD. 
3. RESULTS AND DISCUSSION 
3.1. Chlorarnine- T iodination 
Chloramine-T iodination appeared to be a con- 
venient and reproducible method. In order to 
avoid reducing agents, which can be potentially 
harmful to AVP analogues, to terminate the oxida- 
tion reaction, the reaction mixture was directly in- 
jected onto a HPLC column. Under the 
experimental conditions used, the disulphur bridge 
of the AVP antagonist molecule was not oxidized 
by Chloramine-T. An elution profile of an iodina- 
tion with NaI (fig.la) showed three peaks. Peak 1 
(61% solvent B in A) was identified as the 
nonreacted starting material because of its co- 
migration with pure, unlabelled AVP antagonist, 
and the absence of a bathochrom shift of the UV 
spectrum (h,, = 295 nm) due to the presence of a 
monoiodinated tyrosine. Peak 2 (6Wo B in A) was 
identified as the monoiodinated AVP antagonist 
on the basis of a bathochrom shift (X,, = 
304 nm). Peak 3 (68% B in A) appeared to be 
diiodinated AVP antagonist (h,, = 310 run). Only 
the tyrosyl residue at position 9 was iodinated. No 
iodination took place at the methyltyrosine in posi- 
tion 2 [5]. The tmlabelled monoiodinated AVP an- 
tagonist was used to identify the 1251-AVP 
antagonist on HPLC and to establish inhibition 
constants for AVP and OT receptors (table 1). 
HPLC separation of the reaction products of the 
r2’I-Na iodination showed two peaks of radioac- 
tivity (fig.lb). The first, identified as non- 
incorporated 1251, eluted almost directly in one 
peak (47-50% B in A). Elution of the second 
peak, the “‘1-AVP antagonist, occurred at 
65-66% B in A. Because the stoichiometry of the 
reaction was in disfavour of diiodination only very 
small amounts of diiodinated antagonist were pro- 
duced. The compound was purified in a second 
HPLC step. The 12’1-antagonist coeluted with the 
‘cold’ NaI-Chloramine-T monoiodinated AVP an- 
tagonist, on which basis the ‘2SI-AVP antagonist 
was identified. 
3.2. Biological activities and affinity 
determinations 
The vasopressin antagonist, d(CH&[Tyr- 
(Me)2,Tyr(NH2)g]AVP appeared as a highly potent 
anti-vasopressor and anti-oxytocic peptide with 
Table 1 
Biological activities of AVP antagonist and I-AVP antagonist 
Peptide Anti- Anti-anti- Anti- Anti-oxytocic 
vasopressor diuretic diuretic PAZ 
PAZ p-42 U/mg 
0 mM Mg2+ 0.5 mM Ma’+ 
AVP ant 8.47 f 0.03 6.0 0.002 8.37 f 0.03 8.22 f 0.09 
I-AVP ant 8.17 f 0.06’ ~6.3 0.007 7.50 f 0.06 7.91 f 0.06 
a The iodinated analogue appeared to have a significantly longer duration of 
antagonistic activity in the vasopressor assay 
Antagonistic properties represent PAZ values f SE (of at least 4 
determinations). PAZ is the negative log of AZ, which is the concentration of 
antagonist reducing the response to 2 x units of agonist to equal the response 
to 1 x unit administered before the antagonist 
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low anti-antidiuretic potency and very small an- 
tidiuretic activity (table 1). Iodination of the 
9-tyrosylamide residue slightly reduced the anti- 
vasopressor and anti-oxytocic potencies and slight- 
ly enhanced the anti-antidiuretic potency and 
residual antidiuretic activity. The vasopressin an- 
tagonist and its iodinated counterpart inhibited 
[3H]AVP binding to a Vi (liver) and a VZ (kidney 
medulla) VP receptor and [3H]-[Thr4Gly7]OT 
binding to a OT (uterus) receptor. In line with in 
vivo data, high affinities for the Vi and GT recep- 
tors were found (table 2). Unexpected was the 
observation that d(CH2)s[Tyr-(Me)2,Tyr(NH2)9] 
also bind renal VZ receptors with high affinity. At 
present no explanation can be given for this 
discrepancy between in vivo and in vitro data. 
Monoiodination resulted in increased affinities for 
Vi, VZ and OT receptors, a phenomenon which has 
also been observed for other 94yrosylamide con- 
taining AVP antagonists [3]. Hill plot slopes did 
not differ significantly from unity, indicating an 
interaction with single populations of receptor sites 
in all cases. This was confirmed by regression 
analysis of the untransformed data, conducted 
with Ligand. 
3.3. ‘25I-A VP antagonist binding 
A saturable specific ‘2SI-AVP antagonist 
binding to liver membrane preparations was easily 
revealed (fig.2) due to small non-specific binding. 
Analysis of the data with ligand indicated binding 
to one class of receptor sites with a dissociation 
Table 2 
Affinities of AVP antagonist and I-AVP antagonist 
Peptide Inhibition constants (nM) 
Liver (Vr) Kidney (V2) Uterus (OT) 
AVP ant 0.61 f 0.15 4.0 f 0.2 4.8 f 2.5 
I-AVP ant 0.27 f 0.01 1.0 f 0.1 0.13 f 0.07 
Inhibition constants of the AVP antagonist and I-AVP 
antagonist were determined in competition experiments. Liver, 
kidney medulla and uterus membranes were incubated with 
0.4-l .7 nM [3H]AVP for vasopressin receptors, 1.9-3.1 nM 
[3H]-[Thr4,Gly7]OT for oxytocin receptors and varying 
concentrations of non- and monoiodinated AVP antagonist. 
Values are the mean of two independent determinations in 
triplicate + SD. They were calculated using the non-linear 
weighted least square regression analysis of the untransformed 
data, conducted with ligand 
254 
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Fig.2. Dose-dependent binding of ‘251-labelled (CH&[Tyr- 
(Me)‘,Tyr(NHr)‘]AVP to liver membranes. The figure shows 
the results of a typical experiment. The amount of membrane 
protein was 9.8~~. Filled symbols, specific binding; open 
symbols, non-specific binding. 
constant of 0.28 + 0.09 nM which was in good 
agreement with the value’ found in competition ex- 
periments (Ki = 0.27 + 0.01, table 2). Binding 
capacity was 550 f 85 fmol/mg protein, a value 
which is in the range of thase previously deter- 
mined with [3H]vasopressin [lo]. Radioiodinated 
d(CH2)s[Tyr-(Me)2,Tyr(NH2)9] thus appears as a 
good labelled ligand for Vi vasopressin receptors. 
It is worth noting that its affinity for Vi receptors 
(& = 0.28 nM) is higher than that of t3H]AVP 
(& = 2.0 nM, 1). This property together with a 
high specific radioactivity, 2000 Ci/mmol as com- 
pared to 50-70 Ci/mmol for [3H]AVP will con- 
tribute to considerably reduce the detection limit 
for Vi vasopressin receptors. However, the poor 
selectivity of this new radiolabelled ligand (high af- 
finity for OT receptors and to a lesser extent for VZ 
vasopressin receptors) will impose control ex- 
periments with more selective unlabelled ligands. 
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